BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax. (PubMed, Haematologica) - Oct 2, 2026 - "Combination studies included sonrotoclax, venetoclax, bendamustine, lenalidomide, rituximab, selinexor, and tazemetostat.Tacabrutideg showed single-agent activity in MZL cell lines, inducing BTK degradation and suppression of BCR signaling, MYC targets, and oxidative phosphorylation. Its biological effects largely overlapped with those of zanubrutinib while maintaining complete target degradation...Tacabrutideg demonstrates potent preclinical activity in MZL as a single agent and in combination regimens. Together with the superior activity of sonrotoclax, these findings provide a strong rationale for the clinical evaluation of dual BTK degradation and BCL2 inhibition in patients with MZL."
Journal • Preclinical • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology • BCL2 • BCL2L1 • BTK • MCL1 • PLCG2
|
|
Alberto J Arribas; Alex Zadro; Andrea Rinaldi; Camilla Scalise; Chiara Arrigoni; Davide Rossi; Elisa Civanelli; Emanuele Zucca; Francesco Bertoni; Gianluca Gaidano; Giulio Sartori; Laura Carosella; Luciano Cascione; Matteo Moretti; Nawar Maher; Riccardo Moia; Stefano Raniolo; Vittorio Limongelli
|